YO-01027 (GMP)

YO-01027 (Dibenzazepine) (GMP) is YO-01027 (HY-13526) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. YO-01027 is a potent γ-secretase inhibitor[1][2].

Product Specifications

CAS Number

[209984-56-5]

Product Name Alternative

Dibenzazepine (GMP) ; DBZ (GMP)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Notch; γ-secretase

Type

GMP Small Molecules

Related Pathways

Neuronal Signaling; Stem Cell/Wnt

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/yo-01027-gmp.html

Solubility

10 mM in DMSO

Smiles

O=C(N[C@@H](C)C(N[C@H]1C2=CC=CC=C2C3=CC=CC=C3N(C)C1=O)=O)CC4=CC(F)=CC(F)=C4

Molecular Formula

C26H23F2N3O3

Molecular Weight

463.48

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Ichida JK, et al. Notch inhibition allows oncogene-independent generation of iPS cells. Nat Chem Biol. 2014 Aug;10 (8) :632-639. |[2]Wu J, et al. Dibenzazepine promotes cochlear supporting cell proliferation and hair cell regeneration in neonatal mice. Cell Prolif. 2020 Sep;53 (9) :e12872. |[3]Groth C, et al. Pharmacological analysis of Drosophila melanogaster gamma-secretase with respect to differential proteolysis of Notch and APP. Mol Pharmacol. 2010 Apr;77 (4) :567-74.